Roche’s Gazyva fell short in a late-stage lymphoma trial, jeopardizing the company’s expansion plans for the Rituxan follow-up.

As Celgene gears up to launch Revlimid in Europe for mantle cell lymphoma, it’s already got a familiar foe waiting to receive it.

Valeant has been touting the potential of psoriasis candidate brodalumab to help the struggling company stage its turnaround. But ahead of an advisory…

Drugs companies continue to raise their prices.

Already the world’s best-selling vaccine, Pfizer’s Prevnar 13 got yet another boost Tuesday with an expanded FDA approval in adults aged 18 to 49.

With billions at stake, Amgen’s biosimilar of AbbVie megablockbuster Humira won the unanimous backing of an FDA panel Tuesday, putting the company just an FDA…

Amgen is spending Tuesday making its case for a biosimilar approval before an FDA advisory committee. But come Wednesday, it’ll be Novartis’ Sandoz doing the…

Shire has the approval it’s been waiting for--and the label it wanted, too.

Gilead cancer drug Zydelig--flagged earlier this year after serious adverse events cropped up in studies--can stay on the market with some new recommendations…